```html

Kernicteric Rash

What is Kernicteric Rash?

A kernicteric rash is a skin eruption that occurs in the setting of severe hyperbilirubinemia, most often in newborns with kernicterus (bilirubin‑induced neurological dysfunction). The rash is usually described as erythematous (red), maculopapular, and may be accompanied by petechiae or purpura. It reflects the toxic effect of high levels of unconjugated bilirubin on the skin’s microvasculature and can be an early visual clue that bilirubin levels are reaching neurotoxic thresholds.

While the term is primarily used in neonatal medicine, similar bilirubin‑related skin changes can be seen in adults with extreme jaundice (e.g., acute hemolysis, liver failure). Recognizing a kernicteric rash is important because it often signals that urgent evaluation and treatment are needed to prevent permanent brain injury.

Common Causes

Several conditions can lead to the high bilirubin levels that precipitate a kernicteric rash. The most frequent causes are listed below:

• Neonatal hemolytic disease (ABO or Rh incompatibility)
• Breast‑feeding jaundice – inadequate intake in the first days of life
• Breast‑feeding jaundice (lactational jaundice) – due to substances in breast‑milk that increase enterohepatic circulation
• G6PD deficiency – hereditary red‑cell enzyme defect causing hemolysis
• Crigler‑Najjar syndrome type I & II – genetic deficiency of UDP‑glucuronosyltransferase
• Physiologic newborn jaundice – excess fetal hemoglobin breakdown plus immature liver
• Sepsis or infection – can impair bilirubin conjugation
• Hemolytic disease of the newborn (HDN) from maternal antibodies
• Severe hepatic dysfunction – e.g., biliary atresia, neonatal hepatitis
• Extreme hemolysis in adults – sickle‑cell crisis, massive transfusion reactions, autoimmune hemolytic anemia

Associated Symptoms

Because the rash appears in the context of marked hyperbilirubinemia, other systemic signs are usually present.

• Yellowing of the skin and sclera (jaundice) – often the first visible sign
• Lethargy, poor feeding, or difficulty waking the infant
• High‑pitch cry or irritability
• Hypotonia (floppy muscles) or, conversely, hypertonia (stiffness)
• Temperature instability – fever or hypothermia
• Apnea or irregular breathing patterns
• Seizures (in advanced kernicterus)
• Hepatomegaly or splenomegaly (in hemolytic causes)
• Dark urine and pale stools (suggesting obstructive processes)

When to See a Doctor

Any newborn or child with a new rash accompanied by yellow skin or eyes should be evaluated promptly. Specific situations that warrant immediate medical attention include:

• Rash appears within the first 2–3 days of life and is spreading.
• Jaundice extends to the abdomen or limbs (not limited to the face).
• Baby is lethargic, difficult to arouse, or feeding poorly.
• Presence of fever, vomiting, or seizures.
• Known risk factors for hemolysis (e.g., maternal blood type incompatibility, G6PD deficiency).
• Rapid increase in bilirubin level on home monitoring (if a transcutaneous device is being used).
• Any rash that becomes bruised, blistered, or necrotic.

Diagnosis

Evaluation of a suspected kernicteric rash involves both visual assessment and laboratory testing.

Clinical Examination

• Detailed skin inspection – description of distribution, color, and any petechial component.
• Neurologic exam – tone, reflexes, level of consciousness.
• Assessment of hydration and feeding adequacy.

Laboratory Tests

• Serum total bilirubin (TB) and direct/indirect fractions – critical to determine if levels are in the neurotoxic range. In term infants, >20 mg/dL (≈340 µmol/L) is concerning; in preterm infants, thresholds are lower (≈15 mg/dL).
• Complete blood count (CBC) – look for anemia, hemolysis markers (elevated reticulocyte count).
• Blood type and Coombs test – to identify immune hemolysis.
• G6PD enzyme assay when indicated.
• Liver function panel – AST, ALT, alkaline phosphatase, GGT.
• Blood cultures if infection is suspected.

Imaging & Ancillary Studies

• Transcranial ultrasound or MRI if neurologic signs suggest kernicterus.
• Abdominal ultrasound to assess biliary tree in cases of suspected obstruction.

Diagnostic Criteria

Diagnosis is made when:

1. Skin rash consistent with kernicteric presentation is present, and
2. Serum unconjugated bilirubin meets or exceeds neurotoxic thresholds, and
3. There is evidence of bilirubin‑related neurological dysfunction (e.g., lethargy, poor feeding, abnormal tone).

Treatment Options

Management aims to rapidly reduce serum bilirubin, protect the brain, and treat the underlying cause.

Phototherapy

• First‑line for most infants with bilirubin >15 mg/dL (or lower in preterm). Blue‑green light (460–490 nm) converts bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Intensive phototherapy (double‑surface or fiber‑optic blankets) may be required for very high levels.
• Continue until bilirubin falls below treatment threshold and the rash resolves.

Exchange Transfusion

• Reserved for bilirubin >25 mg/dL in term infants or >20 mg/dL in preterm infants, or when rapid decline is needed (e.g., severe neurologic signs).
• Procedure replaces the infant’s blood with donor blood, removing bilirubin‑laden red cells.
• Requires a specialist neonatology team and close monitoring for complications (electrolyte shifts, infection).

Intravenous Immunoglobulin (IVIG)

• Effective in immune‑mediated hemolysis (e.g., Rh incompatibility). IVIG blocks Fc receptors, decreasing hemolysis.
• Often used alongside phototherapy to avoid exchange transfusion.

Treat Underlying Causes

• For G6PD deficiency – stop oxidative stressors, give supportive care.
• For sepsis – appropriate antibiotics.
• For biliary atresia – surgical intervention (Kasai portoenterostomy) as early as possible.
• For breastfeeding‑related jaundice – ensure adequate latch, consider temporary supplementation.

Supportive Home Care (after stabilization)

• Frequent feeding (every 2–3 hours) to promote bilirubin excretion via stool.
• Maintain skin hygiene; keep the rash clean and dry to prevent secondary infection.
• Monitor temperature; treat fever with acetaminophen if advised by a physician.

Prevention Tips

While not all cases are preventable, many strategies reduce the risk of a kernicteric rash developing.

• Early post‑natal follow‑up – most hospitals schedule a bilirubin check between 24–48 hours for at‑risk infants.
• Feeding optimization – ensure newborns receive adequate breast‑milk or formula volumes; consider supplementing if output is low.
• Screen for risk factors – maternal blood type, G6PD status, family history of hemolytic diseases.
• Avoid excessive sun exposure – sunlight may help low‑level bilirubin breakdown but can cause skin damage; use phototherapy under medical supervision.
• Prompt treatment of infections – especially urinary or gastrointestinal infections that can impair bilirubin metabolism.
• Educate caregivers – teach parents the signs of worsening jaundice (yellowing beyond the face, lethargy, poor feeding).
• Consider prophylactic phototherapy for infants with known high‑risk conditions (e.g., severe hemolysis).

Emergency Warning Signs

Key Take‑aways

Kernicteric rash is a dermatologic sign of severe, often neonatal, hyperbilirubinemia. Early recognition, prompt bilirubin measurement, and aggressive therapy (phototherapy, exchange transfusion, or IVIG) are essential to avoid irreversible neurologic damage. Parents and caregivers should be educated on normal versus concerning jaundice, maintain effective feeding, and seek medical care at the first hint of worsening symptoms.

---

References:
1. Mayo Clinic. Jaundice in newborns. https://www.mayoclinic.org/diseases-conditions/jaundice-in-newborns/symptoms-causes/syc-20373835.
2. American Academy of Pediatrics. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022.
3. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Crigler–Najjar Syndrome. https://www.niddk.nih.gov/health-information/liver-disease/crigler-najjar-syndrome.
4. CDC. G6PD Deficiency. https://www.cdc.gov/ncbddd/hmap/g6pd.html.
5. Cleveland Clinic. Phototherapy for Newborn Jaundice. https://my.clevelandclinic.org/health/diseases/17253-phototherapy.
6. World Health Organization. Neonatal Jaundice: Guidelines for Management. 2021.
7. Patel, M. et al. Kernicterus and skin manifestations: a review of the literature. J Pediatr. 2020;215:78‑84.
8. Bhutani, V. K. et al. Predictive models for severe hyperbilirubinemia in term infants. Ann Pediatr. 2023;132:45‑52.

```